Merck signs exclusive global license with SciBrunch for KRAS G12D drug SPR2015 in USD 2.13 billion deal

PUBT · 2d ago
Merck signs exclusive global license with SciBrunch for KRAS G12D drug SPR2015 in USD 2.13 billion deal
  • Merck signed an exclusive global license with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor.
  • Deal grants worldwide rights to develop, manufacture, commercialize SPR2015.
  • SciBrunch to receive USD 400 million upfront.
  • Milestone payments could lift total potential deal value to USD 2.13 billion across multiple indications.
  • Merck expects a USD 400 million pre-tax charge in Q3 2026, about USD 0.13 per share.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609280645BIZWIRE_USPR_____20260928_BW125137) on September 28, 2026, and is solely responsible for the information contained therein.